Aehr Test Systems (AEHR) director bought 20,000 shares at $15.50. He just filed to sell the same block near $109.

Aehr Test Systems (AEHR) director bought 20,000 shares at $15.50. He just filed to sell the same block near $109.

Key points

  • Aehr Test Systems director Howard Slayen filed a Form 144 on August 4, 2026 covering 20,000 shares valued at $2,179,600.
  • He bought that same 20,000-share block on the open market on August 2, 2024 at $15.50, a cost of $310,000.
  • The notice prices the stock at $108.98, seven times what he paid, for a gain of $1,869,600.
  • Of the 14 notices filed that day, his is the only one covering stock an insider bought instead of receiving as pay.
  • Slayen sold on three earlier occasions since November 2025 and still reported 166,367 shares on July 30.

Fourteen insiders filed notices to sell stock on Tuesday, and we read those the way you'd read a friend's brokerage statement. Thirteen of them tell one story. Shares vested and got sold, or options were exercised and cashed out the same afternoon. That's what a Form 144 usually is. It's closer to payday than to a market call.

The fourteenth belongs to Howard Slayen, a director at Aehr Test Systems (AEHR) in Fremont, California. Every notice filed with the SEC carries a box describing how the insider got the stock. Where the other thirteen say Restricted Stock Vesting or Stock Option Exercise, Slayen's says Open market purchase.

The date beside that phrase is August 2, 2024, and his Form 4 from that day puts the trade on a single line. Twenty thousand shares. Transaction code P. Fifteen dollars fifty a share. That's $310,000 of his own money, and the Rule 10b5-1 box on it sits unchecked, so Slayen picked the day himself. It took his reported holding to 220,714 shares. Tuesday's notice covers 20,000 shares through Charles Schwab, the same twenty thousand, valued at $2,179,600. Divide it out and you get $108.98 apiece. Two years and two days after buying the block, he's filed to sell it for a gain of $1,869,600.

That distance between $15.50 and $108.98 is why this notice came out of the pile. A director selling stock the company handed him tells you about his pay package. A director selling stock he went to the open market for is closing a position he opened, and here the entry price is public.

He has been selling the whole way up

Seven times your money sounds like a man who waited two years and took his shot. Slayen's other filings describe someone who's been at this since last autumn.

DateFilingWhat it wasSharesPrice
Aug 2, 2024Form 4Open market buy20,000$15.50
Nov 5, 2025Form 4Sale6,000$25.73
Feb 4, 2026Form 4Three gifts15,000no consideration
Apr 17, 2026Form 4Sale25,000$85.00
Apr 22, 2026Form 4Gift1,800no consideration
May 13, 2026Form 4Sale6,819$104.73
Jul 1, 2026Form 4Share award1,658no consideration
Jul 30, 2026Form 4Gift5,000no consideration
Aug 4, 2026Form 144Notice to sell20,000$108.98 stated

Three sales at $25.73 in November, $85.00 in April and $104.73 in May, each one higher than the last. Add 21,800 shares given away across three separate gift filings this year, in February, April and July. His reported holding has gone from 220,714 in August 2024 to 166,367 on July 30, and that July figure still counts restricted stock units waiting to vest. Tuesday's 20,000 shares are around twelve percent of what he holds. So Slayen is a director selling down a large stake into a rising stock, and the block going out this week happens to be the one he paid cash for. Both descriptions fit the same man.

What the stock did to get here

Aehr builds test and burn-in equipment for semiconductors, and the demand story attached to it right now runs through AI processors and silicon photonics. The company reported its fiscal fourth quarter on July 14. Revenue came in at $18.8 million against $14.1 million a year earlier. Non-GAAP profit was $0.11 a diluted share where the year before had been a small loss. Quarterly bookings hit a record $60.7 million, and effective backlog counting orders taken since the quarter closed reached $100.6 million.

The full fiscal year reads more plainly than the quarter does. Revenue for fiscal 2026 was $50.0 million, down from $59.0 million. Guidance is what moved the stock. Chief executive Gayn Erickson told investors Aehr has "substantial visibility into projected fiscal 2027 revenue of $130 million to $150 million", which he put at growth of 160 to 200 percent.

Trading on Nasdaq closed at $91.71 on Monday, and Tuesday morning, the day Slayen's notice was filed, Aehr announced another follow-on production order from its lead silicon photonics customer for a FOX-XP system. Erickson called it "another indication that silicon photonics is moving from technology adoption into manufacturing scale-up". The stock closed the session at $109.89, up 19.8 percent on the day. Aehr has now announced three of those photonics orders since June 17, so the run into this week has been built on a steady drip of them.

A Form 144 sets a ceiling on what an insider may sell, and Slayen has told Schwab he intends to sell on or after August 4. The actual sale can come in smaller or be dropped entirely. The Form 4 that follows within two business days is where an executed trade shows up, and it's also where a Rule 10b5-1 plan gets disclosed by checkbox. His notice leaves the plan field blank. So did the Forms 4 behind all three of his earlier sales, which our insider tracker flags as an insider's own call.

The public record stops at the trade itself, which leaves the motive an open question. Directors sell for tax bills, houses, divorces and plain diversification when most of a person's net worth sits in one small-cap semiconductor company, and the filing stays quiet about which of those applies to Slayen. What it does hand you, unusually for a sale, is his cost. We looked at whether following filings like this actually works in a separate piece, and at how prescheduled selling plans differ from a discretionary sale here. Aehr filings land on the company's filings page as they arrive, and the Form 4 confirming this one is due within two business days of whenever he sells.

Sources

  • SEC Form 144 for Howard T. Slayen, Aehr Test Systems, filed August 4, 2026 (accession 0001949846-26-000462), stating 20,000 shares, $2,179,600, acquired August 2, 2024 by open market purchase
  • SEC Form 4 for Howard T. Slayen filed August 2, 2024 (accession 0001593968-24-001046), transaction code P, 20,000 shares at $15.50
  • SEC Forms 4 for Slayen filed November 5, 2025 and April 17, April 22, May 15 and July 30, 2026, covering his sales, gifts and reported holdings
  • Aehr Test Systems fiscal 2026 fourth quarter results, 8-K and Exhibit 99.1 filed July 14, 2026
  • Aehr Test Systems press release, August 4, 2026, on a follow-on production order from its lead silicon photonics customer

Frequently asked questions

Why is an Aehr Test Systems director selling 20,000 shares?

Aehr Test Systems (AEHR) director Howard T. Slayen filed a Form 144 with the SEC on August 4, 2026 covering 20,000 shares valued at $2,179,600, to be sold on or after that date through Charles Schwab. The notice does not give a reason, and no filing requires one. What makes it unusual is the acquisition box, which reads Open market purchase rather than the restricted stock vesting or option exercise wording that appeared on the other 13 Form 144 notices filed that day. A Form 144 is a notice of intent, so the sale can come in smaller or be dropped entirely.

How much did Aehr director Howard Slayen pay for the shares he is selling?

$15.50 a share, or $310,000 for the 20,000-share block. His Form 4 filed August 2, 2024 records the purchase under transaction code P, the code for an open market buy, and it took his reported holding to 220,714 shares. The August 4, 2026 Form 144 values the same 20,000 shares at $2,179,600, which works out to $108.98 each. That is a gain of $1,869,600 on the block, seven times his cost, held two years and two days.

Is the Aehr insider sale part of a 10b5-1 trading plan?

The notice leaves the plan adoption field blank, and so did the Forms 4 behind Slayen's three earlier sales in November 2025, April 2026 and May 2026. A Form 144 is not the authoritative document for this question. The Form 4 that reports the completed sale carries an actual Rule 10b5-1 checkbox, and it is due within two business days of the trade. On the record as it stands, AIStockWire's insider tracker classifies this notice as the insider's own call.

How many Aehr shares does Howard Slayen still own?

166,367 as of his Form 4 dated July 30, 2026, a figure that includes restricted stock units still waiting to vest. The 20,000 shares covered by the August 4 notice are around twelve percent of that. His holding has come down from 220,714 shares in August 2024 through three sales, 6,000 shares at $25.73 in November 2025, 25,000 at $85.00 in April 2026 and 6,819 at $104.73 in May 2026, plus 21,800 shares given away across three gift filings in February, April and July 2026.

What did Aehr Test Systems report for fiscal fourth quarter 2026?

Aehr reported on July 14, 2026 for the quarter ended May 29, 2026. Revenue was $18.8 million against $14.1 million a year earlier, GAAP net income was $1.4 million or $0.04 a diluted share, and non-GAAP net income was $3.6 million or $0.11 a diluted share. Quarterly bookings were a record $60.7 million and effective backlog, including orders taken since the quarter closed, was $100.6 million. Full fiscal 2026 revenue was $50.0 million, down from $59.0 million in fiscal 2025. Chief executive Gayn Erickson guided fiscal 2027 revenue to $130 million to $150 million, growth of approximately 160 to 200 percent.

More on AEHR

Jennifer Song
Jennifer Song

Jennifer Song writes Portfolio Watch. She studied finance and likes digging through public filings to see what politicians and other well-known people are buying and selling. She doesn't trade herself. She just likes seeing where the big names put their money.